ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026
Exploring the lived experiences of women with metastatic breast cancer and their HRQoL questionnaire preferences: a qualitative study.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of CORe-MBC: a pragmatic measure of participatory care for adults with metastatic breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundManaging health-related quality of life (HRQoL) in patients with metastatic breast cancer (MBC) is crucial due to the physical, emotional, and social burdens of disease and its treatments. This study examined the HRQoL of patients with MBC and compared the patients' perspectives of two validated tools-the Functional Assessment of Cancer Therapy - Breast (FACT-B) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire QLQ-C30 with its breast cancer-specific module QLQ-BR42 (EORTC) to determine which is most suitable for assessing HRQoL in patients with MBC.
methodsA qualitative study design was used to explore patients' HRQoL and their perspectives on the two questionnaires, FACT-B versus EORTC, focusing on what matters most to the patients. Individual interviews were conducted between September and December 2024 at the Department of Oncology, Odense University Hospital, Denmark. Thematic analysis was selected to extract and analyze data.
resultsFifteen women with MBC were included. Median age was 62 years (range 28-79), and the median duration of the interviews was 21 min (range 13-32 min). The analysis identified three main themes: (1) Living with metastatic disease, when incurable cancer is a life condition, (2) Design of the questionnaires, 3) Content of the questionnaires. Participants described impaired HRQoL, as they were hindered in living an everyday life, felt lonely at times, engaged in protective buffering, and lived in fear of the next scan. Overall, the participants found the design of the two questionnaires acceptable; neither was preferred over the other. However, regarding the content, the participants expressed a clear preference for FACT-B over the EORTC, primarily due to its greater relevance to their current situation, reflecting everyday life and need for support.
conclusionsParticipants in this study reported impaired HRQoL, marked by disrupted daily life, loneliness, protective buffering, and scanxiety. They preferred the FACT-B over the EORTC questionnaire for measuring HRQoL because of its focus on personal and emotional aspects, which reflected their lived experiences. However, further research is warranted to validate these findings in more diverse populations in the metastatic breast cancer context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.